Edition:
United States

Swedish Orphan Biovitrum AB (publ) (SOBIV.ST)

SOBIV.ST on Stockholm Stock Exchange

123.10SEK
11:29am EDT
Change (% chg)

0.20kr (+0.16%)
Prev Close
122.90kr
Open
122.50kr
Day's High
123.30kr
Day's Low
122.50kr
Volume
279,469
Avg. Vol
631,718
52-wk High
143.80kr
52-wk Low
89.50kr

SOBIV.ST

Chart for SOBIV.ST

About

Swedish Orphan Biovitrum publ AB is a Sweden-based pharmaceutical company. The Company develops, manufactures and sells medications within hemophilia, autoimmune diseases, metabolic diseases and cancer supportive care. The Company’s product portfolio is divided into three business segments: the Core Products segment offers... (more)

Overall

Beta: 1.69
Market Cap(Mil.): kr33,230.90
Shares Outstanding(Mil.): 270.39
Dividend: --
Yield (%): --

Financials

  SOBIV.ST Industry Sector
P/E (TTM): 45.72 31.70 32.82
EPS (TTM): 2.69 -- --
ROI: 8.68 15.41 14.97
ROE: 12.91 16.43 16.21

BRIEF-Sobi Q2 EBITA falls, raises 2017 guidance

* Swedish orphan biovitrum Q2 total revenue was SEK 1,639 mln (1,469)

Jul 19 2017

BRIEF-Sobi says COO Raffensperger to leave the company

* Says company and Raffensperger, have come to the agreement that Raffensperger will leave the company to pursue other opportunities. Source text for Eikon: Further company coverage: (Stockholm Newsroom)

Jun 07 2017

BRIEF-Sobi ends discussions to sell Partner Products business area

* Sobi keeps the Partner Products business area as an integral part of the company

Jun 05 2017

BRIEF-Sobi appoints Guido Oelkers as new CEO

* Oelkers joins Sobi from his previous role as CEO at BSN Medical GmbH

May 04 2017

BRIEF-Sobi Q1 EBITA SEK 406 mln, repeats outlook

* Says Q1 revenues grew 10 per cent overall, and by 47 percent adjusted for the one-time credit of SEK 322 million received in Q1 2016.

Apr 28 2017

Earnings vs. Estimates